Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Paradigm Biopharmaceuticals ( (AU:PAR) ) has shared an update.
Paradigm Biopharmaceuticals has disclosed changes in director Paul Rennie’s interests in the company’s securities, detailing movements across fully paid ordinary shares, listed options, performance rights and unlisted piggyback options. The update, filed under ASX listing rules, provides investors with transparency on the director’s direct and indirect holdings, including those held via self‑managed superannuation and family trust structures, and reflects ongoing adjustments to his equity exposure in the company.
The notice outlines the expiry dates and exercise prices associated with the various classes of securities, confirming both existing positions and newly acquired or granted instruments. This level of disclosure helps shareholders assess potential alignment between executive incentives and long‑term company performance, while signalling the scale and structure of a key director’s stake in Paradigm Biopharmaceuticals.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.27 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited is an Australian biopharmaceutical company focused on developing and commercialising therapeutic products. The company is listed on the ASX and issues fully paid ordinary shares, listed options, performance rights and other equity-linked securities as part of its capital management and executive remuneration structures.
YTD Price Performance: -14.71%
Average Trading Volume: 900,270
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$127.4M
Find detailed analytics on PAR stock on TipRanks’ Stock Analysis page.